mProX™ Human KIR2DL1 Stable Cell Line

Product Information

Target Family

Immune Checkpoint

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;YTS

Target Classification

Immune Checkpoint Cell Lines

Target Research Area

Immunology Research

Related Diseases

Chronic Nk-Cell Lymphocytosis; Behcet Syndrome

Gene ID

Human:3802

UniProt ID

Human:P43626

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The applications of KIR2DL1 include its role in gene activation and expression control, its association with COVID-19 disease risk and protective factors, its potential as a therapeutic target in glioblastoma immunotherapy, and its involvement in immune infiltration in endometriosis. In terms of gene activation, the KIR2DL1 intermediate upstream element is found to participate in gene activation and is required for efficient gene activation. In the context of COVID-19, certain HLA/KIR polymorphisms, including KIR2DL1, have been associated with disease risk and protection. In glioblastoma immunotherapy, the blockade of KIR2DL1 has been shown to attenuate the antitumor effects of expanded and activated human primary natural killer cells. Lastly, in endometriosis, KIR2DL1 is identified as one of the central genes related to immune infiltration, providing insights into the immunology and molecular mechanisms of the disease.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human KIR2DL1 Stable Cell Line (S01YF-1023-PY182). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Morgan Garcia (Verified Customer)

What is the role of KIR2DL1 in immune surveillance? Oct 27 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

KIR2DL1 is involved in the regulation of natural killer (NK) cell activity and plays a crucial role in immune surveillance, particularly in the context of cancer and viral infections. Oct 27 2023

chat Casey Jones (Verified Customer)

How does KIR2DL1 influence the efficacy of cancer treatments? Oct 14 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

The expression and genetic variations of KIR2DL1 can influence the response to cancer treatments, including immunotherapies. It can affect NK cell-mediated cytotoxicity against tumor cells. Oct 14 2022

Published Data

Fig.1 Imaging YTS-GFP-KIR2DL1 cells via confocal immunofluorescence microscopy after stimulation with either an isotype control anti-IgG or a monoclonal antibody targeting KIR2DL1.

The cells were stimulated with anti-KIR2DL1 mAb or anti-IgG2b (an isotype control), and subsequent examination was performed using confocal microscopy. Clustering of KIR2DL1 on the plasma membrane, along with SV, was observed upon stimulation with anti-KIR2DL1 mAb. However, no alteration was detected in either the distribution of KIR2DL1 or the co-localization of SV with KIR2DL1 when stimulated with anti-IgG2b (an isotype control). Hence, it is inferred that the dependence of SV interaction with KIR2DL1 is linked to receptor stimulation.

Ref: Liu, Hai-Peng, et al. "Association of supervillin with KIR2DL1 regulates the inhibitory signaling of natural killer cells." Cellular signalling 23.2 (2011): 487-496.

Pubmed: 21070852

DOI: 10.1016/j.cellsig.2010.11.001

Research Highlights

W Wright, Paul. et al. "The KIR2DL1 intermediate upstream element participates in gene activation." Immunogenetics, 2023.
The human KIR genes encode a family of class I MHC receptors expressed by subsets of NK cells. The stochastic process controlling KIR protein expression suggests competition between sense and antisense promoter elements for the variegated expression of these genes. Prior research highlights distinct roles of distal, intermediate, and proximal sense promoter/enhancer elements in gene activation and expression. Additionally, proximal and intronic antisense promoter transcripts have been linked to gene silencing during NK cell development. The current study investigates the effect of intermediate promoter deletion on KIR2DL1 expression in the YTS cell line. Results indicate that deletion of the intermediate element does not impact proximal promoter activity, but does increase detection of upstream transcripts. No significant changes in alternative mRNA splicing or expression of KIR2DL1 protein were noted. However, the deletion is associated with a reduced frequency of gene activation by 5-azacytidine, suggesting that the intermediate element is not an enhancer required for KIR expression, but rather plays a role in efficient gene activation.
W Wright, Paul. et al. "The KIR2DL1 intermediate upstream element participates in gene activation." Immunogenetics, 2023.
Pubmed: 37801092 DOI: 10.1007/s00251-023-01321-9

Balas, Antonio. et al. "Coronavirus-19 disease risk and protective factors associated with HLA/KIR polymorphisms in Ecuadorian patients residing in Madrid." Human immunology, 2023.
In a study conducted on a Spanish cohort of hospitalized patients with COVID-19, it was found that 21.8% of cases were represented by immigrants. This percentage surpassed the proportion of immigrants in the total population of the region. The study also looked at ethnic-related genetic risk factors for the disease, specifically focusing on human leukocyte antigen (HLA) genotypes and natural killer-activating and inhibitory receptors. The results suggest that these genetic differences may influence the immune response to SARS-CoV-2 infection and its progression.
Balas, Antonio. et al. "Coronavirus-19 disease risk and protective factors associated with HLA/KIR polymorphisms in Ecuadorian patients residing in Madrid." Human immunology, 2023.
Pubmed: 37777360 DOI: 10.1016/j.humimm.2023.09.004